Literature DB >> 18848856

Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.

Niels Hagenaars1, Enrico Mastrobattista, Harrie Glansbeek, Jacco Heldens, Han van den Bosch, Virgil Schijns, Didier Betbeder, Herman Vromans, Wim Jiskoot.   

Abstract

In order to study the influence of antigen composition, spatial organization of antigen and the route of administration, four cell culture-derived, inactivated, nonadjuvanted influenza vaccine formulations, i.e. whole inactivated virus (WIV), split, subunit and virosome vaccines were prepared from a single antigen batch. We directly compared the immunogenicity and efficacy of these vaccine formulations after intramuscular (i.m.) or intranasal (i.n.) administration in mice. Prime and boost vaccination were followed by a potentially lethal homologous aerosol challenge. For all vaccines, the i.m. route induced higher serum humoral immune responses as compared to the i.n. route and protected all mice against challenge at a dose of 5 microg. Upon i.n. immunization only WIV and split vaccines induced detectable IgG titers and partial protection against challenge but only very low HI titers were induced in almost all mice. WIV induced mainly IgG2a/c titers via both routes, whereas split vaccine induced exclusively IgG1 titers via both routes. Subunit and virosome vaccines induced exclusively IgG1 via the i.m. route. Mucosal sIgA levels were only detected after i.n. vaccination with WIV. Furthermore, vaccines containing all viral components (WIV and split vaccine) induced higher serum HI titers and serum antibody titers than subunit and virosome vaccines. The differences in magnitude and quality of immune responses of split and WIV, having the same composition, are likely related to their distinct spatial organization. In conclusion, the direct comparison between WIV, split, subunit and virosomes, shows that the differences in immune responses between these well known influenza vaccines can be explained by both the composition and particulate structure of these vaccine formulations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18848856     DOI: 10.1016/j.vaccine.2008.09.057

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  26 in total

1.  Proteomic characterization of influenza H5N1 virus-like particles and their protective immunogenicity.

Authors:  Jae-Min Song; Chi-Won Choi; Sang-Oh Kwon; Richard W Compans; Sang-Moo Kang; Seung Il Kim
Journal:  J Proteome Res       Date:  2011-07-08       Impact factor: 4.466

2.  CpG DNA assists the whole inactivated H9N2 influenza virus in crossing the intestinal epithelial barriers via transepithelial uptake of dendritic cell dendrites.

Authors:  Y Yin; T Qin; X Wang; J Lin; Q Yu; Q Yang
Journal:  Mucosal Immunol       Date:  2014-12-10       Impact factor: 7.313

Review 3.  Current prospects and future challenges for nasal vaccine delivery.

Authors:  Helmy Yusuf; Vicky Kett
Journal:  Hum Vaccin Immunother       Date:  2016-12-09       Impact factor: 3.452

4.  Inhibiting influenza virus replication and inducing protection against lethal influenza virus challenge through chitosan nanoparticles loaded by siRNA.

Authors:  Abbas Jamali; Fatemeh Mottaghitalab; Asghar Abdoli; Meshkat Dinarvand; Aida Esmailie; Masoumeh Tavassoti Kheiri; Fatemeh Atyabi
Journal:  Drug Deliv Transl Res       Date:  2018-02       Impact factor: 4.617

5.  Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice.

Authors:  Fu-Shi Quan; Aswani Vunnava; Richard W Compans; Sang-Moo Kang
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

6.  Preservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures.

Authors:  Felix Geeraedts; Vinay Saluja; Wouter ter Veer; Jean-Pierre Amorij; Henderik W Frijlink; Jan Wilschut; Wouter L J Hinrichs; Anke Huckriede
Journal:  AAPS J       Date:  2010-03-02       Impact factor: 4.009

7.  Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine.

Authors:  Subash C Das; Masato Hatta; Peter R Wilker; Andrzej Myc; Tarek Hamouda; Gabrielle Neumann; James R Baker; Yoshihiro Kawaoka
Journal:  Vaccine       Date:  2012-09-16       Impact factor: 3.641

8.  Physicochemical and immunological characterization of N,N,N-trimethyl chitosan-coated whole inactivated influenza virus vaccine for intranasal administration.

Authors:  Niels Hagenaars; Enrico Mastrobattista; Rolf J Verheul; Imke Mooren; Harrie L Glansbeek; Jacco G M Heldens; Han van den Bosch; Wim Jiskoot
Journal:  Pharm Res       Date:  2009-02-18       Impact factor: 4.200

Review 9.  Animal models for the study of influenza pathogenesis and therapy.

Authors:  Dale L Barnard
Journal:  Antiviral Res       Date:  2009-01-25       Impact factor: 5.970

10.  Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant.

Authors:  Vinay Saluja; Jean P Amorij; Maarten L van Roosmalen; Kees Leenhouts; Anke Huckriede; Wouter L J Hinrichs; Henderik W Frijlink
Journal:  AAPS J       Date:  2010-01-08       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.